

ABSTRACT

5 The present invention relates to therapeutic combinations of [9-[*R*-2-[[*(S)*-[[*(S)*-
1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
(GS-7340) and (2*R*, 5*S*, *cis*)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-
yl)-(1*H*)-pyrimidin-2-one (emtricitabine, (-)-*cis* FTC, Emtriva™) and their
physiologically functional derivatives. The combinations may be useful in the
10 treatment of HIV infections, including infections with HIV mutants bearing resistance
to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned
with pharmaceutical compositions and formulations of said combinations of GS-7340
and emtricitabine, and their physiologically functional derivatives, as well as
therapeutic methods of use of those compositions and formulations.

15